MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:SDZNY)

82.58 -1.97 (-2.33%)
Delayed Quote Updated: 3:58 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,277
Open 83.78
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 84.55
Today's Range 82.16 - 83.79
52wk Range 55.42 - 94.15
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy

Performance

YTD
+13.1%
+13.1%
1 Month
-2.6%
-2.6%
3 Month
-7.9%
-7.9%
6 Month
+2.9%
+2.9%
1 Year
+47.0%
+47.0%

More News

Read More
News headline image
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
From Sandoz
Via Business Wire
News headline image
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
From Sandoz Group
Via GlobeNewswire
News headline image
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor ↗
Via Benzinga
Topics Intellectual Property
News headline image
Life Sciences Investor Forum: Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
From Sandoz Group
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for June 11th-12th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
From Sandoz Group
Via GlobeNewswire
News headline image
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug ↗
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz reports strong FY 2024 results and Q4 2024 sales
From Sandoz Group
Via GlobeNewswire
News headline image
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗
Via Benzinga
News headline image
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
From Sandoz Group
Via GlobeNewswire
News headline image
Francisco Ballester to retire; Peter Stenico appointed President Region International
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
From Sandoz Group
Via GlobeNewswire
News headline image
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
From Sandoz Group
Via GlobeNewswire

Frequently Asked Questions

Is SDZNY publicly traded?
Yes, SDZNY is publicly traded.
What exchange does SDZNY trade on?
SDZNY trades on the OTC Traded
What is the ticker symbol for SDZNY?
The ticker symbol for SDZNY is SDZNY on the OTC Traded
What is the current price of SDZNY?
The current price of SDZNY is 82.58
When was SDZNY last traded?
The last trade of SDZNY was at 10/01/26 03:58 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story